As evidence mounts linking obesity to the microbiome, three independent studies have identified separate ways of harnessing gut microbiota to treat the condition. The spectrum of approaches, which involve a bacterial protein, a bacterial species and a gut signature, reflects the complexity and new thinking involved in harnessing the microbiome for therapeutics, and is likely a sign of the broad strategies companies will need to adopt to make headway in the rapidly emerging field.
The three papers were published late last year in different Nature journals, and have thus far translated into an early clinical trial and plans for a spinout, with two of the groups fast to file IP.
The third group declined to disclose the IP status for this study. However, a microbiome analysis platform developed by the same investigators was spun out to create RondinX, whose launch was announced last week.
While early translational work on the microbiome aimed at treating a handful of gastrointestinal (GI) disorders and infections, rapid scientific progress has opened a wide range of therapeutic and diagnostic applications, and spawned a steady stream of newcos and pharmas getting into the game.
For gut-related diseases, the list of indications and strategies is growing as research uncovers how GI microbes can exert effects on distant tissues by modulating immune function, metabolism and the gut-brain axis. For example, several companies are exploring microbiome-based therapies